Polar Asset Management Partners Inc. Immunovant, Inc. Transaction History

Polar Asset Management Partners Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $597,380 - $752,318	23,800 Added 46.21%	75,300 $1.99 Million
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $1.56 Million - $2.26 Million	51,500 New	51,500 $1.66 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $4.49 Million - $6.34 Million	-143,400 Reduced 92.22%	12,100 $509,000
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $9,275 - $19,980	500 Added 0.32%	155,500 $5.97 Million
Q2 2023 Aug 14, 2023	SELL	$14.2 - $23.75 $5.3 Million - $8.86 Million	-373,000 Reduced 70.64%	155,000 $2.94 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $3.48 Million - $9.37 Million	528,000 New	528,000 $9.37 Million
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $1.18 Million - $1.97 Million	-348,400 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $1.74 Million - $2.21 Million	237,600 Added 214.44%	348,400 $2.97 Million
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $776,708 - $1.26 Million	110,800 New	110,800 $963,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

Stay updated on Polar Asset Management Partners Inc. with notifications on news.